04:24 AM EDT, 03/20/2026 (MT Newswires) -- Novo Nordisk's ( NVO ) weight-loss drugs in India are about to face steep price cuts after the introduction of generic versions this month with the expiration of patents, Bloomberg reported Friday.

At least 12 companies are expected to immediately launch injectable versions of semaglutide with prices as low as 1,290 ($13.82) rupees a month, compared with the 10,480 rupees for Novo Nordisk's ( NVO ) Wegovy pen, the report said.

More than 40 drug manufacturers are expected to launch products under more than 50 brand names this year, the report said.

Canada's patents expired in January, while China, Brazil, and Turkey's patents are set to expire this year, the report said.

Novo Nordisk ( NVO ) did not immediately reply to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)